Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Net Cash Flow (2018 - 2025)

10x Genomics' Net Cash Flow history spans 8 years, with the latest figure at $41.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 176.57% year-over-year to $41.2 million; the TTM value through Dec 2025 reached $129.4 million, up 959.73%, while the annual FY2025 figure was $129.4 million, 959.73% up from the prior year.
  • Net Cash Flow for Q4 2025 was $41.2 million at 10x Genomics, up from $35.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $112.4 million in Q1 2023 and bottomed at -$275.9 million in Q1 2022.
  • The 5-year median for Net Cash Flow is -$6.2 million (2023), against an average of -$10.8 million.
  • The largest annual shift saw Net Cash Flow tumbled 903.58% in 2022 before it surged 1051.66% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$12.9 million in 2021, then dropped by 11.91% to -$14.4 million in 2022, then surged by 407.79% to $44.5 million in 2023, then tumbled by 221.03% to -$53.8 million in 2024, then soared by 176.57% to $41.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Net Cash Flow are $41.2 million (Q4 2025), $35.0 million (Q3 2025), and $20.3 million (Q2 2025).